US FTC: pay-for-delay deals jump
This article was originally published in SRA
Executive Summary
The US Federal Trade Commission has said that deals in which biopharmaceutical innovators pay generic drug makers under patent settlement agreements to delay entrance of their copycat products into the US marketplace jumped from 28 in fiscal year 2011 to 40 in FY 2012 – the highest since 20031,2.